CN111700957A - Composition for preventing and treating porcine reproductive and respiratory syndrome and preparation method and application thereof - Google Patents
Composition for preventing and treating porcine reproductive and respiratory syndrome and preparation method and application thereof Download PDFInfo
- Publication number
- CN111700957A CN111700957A CN202010788546.3A CN202010788546A CN111700957A CN 111700957 A CN111700957 A CN 111700957A CN 202010788546 A CN202010788546 A CN 202010788546A CN 111700957 A CN111700957 A CN 111700957A
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- respiratory syndrome
- porcine reproductive
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/413—Gall bladder; Bile
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/758—Zanthoxylum, e.g. pricklyash
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Nutrition Science (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides a composition for preventing and treating porcine reproductive and respiratory syndrome, and a preparation method and application thereof. A composition for preventing and treating porcine reproductive and respiratory syndrome comprising: 40-50 parts of alpha-glycerol monolaurate, 30-40 parts of Chinese herbal medicines, 10-20 parts of acidifier and 5-10 parts of plant essential oil; the Chinese herbal medicine comprises, by weight, 20-30 parts of mulberry leaves, 20-30 parts of moringa seeds, 15-25 parts of bezoar and 10-20 parts of blackberrylily rhizome. The preparation method of the composition comprises the following steps: mixing raw materials including alpha-monolaurin, Chinese medicinal materials, acidifier and plant essential oil to obtain the composition. The application of the composition in preparing a medicament for preventing and treating porcine reproductive and respiratory syndrome. The composition provided by the application can improve the growth performance of piglets, improve the immunity of piglets, resist viruses, inhibit the propagation of virus proliferation and effectively prevent and treat the porcine reproductive and respiratory syndrome.
Description
Technical Field
The invention relates to the field of veterinary drugs, and in particular relates to a composition for preventing and treating porcine reproductive and respiratory syndrome, and a preparation method and application thereof.
Background
Porcine Reproductive and Respiratory Syndrome (PRRS) is a reproductive disorder and respiratory infectious disease caused by an enveloped single-stranded positive-stranded RNA virus. The ear of some sick pigs is purple, so it is also called as "blue ear disease". The blue ear disease is a highly contagious disease, is transmitted through the oral-nasal genital tract, and is clinically characterized by reproductive disorders such as abortion, premature birth, stillbirth and mummy of pregnant sows, anorexia, fever and respiratory disorders of pigs of all ages (particularly piglets). The porcine reproductive and respiratory syndrome virus can be transmitted to piglets from pregnant sows through placentas, and the death rate of the piglets infected with the porcine reproductive and respiratory syndrome virus is extremely high. The different subtype strains of the porcine reproductive and respiratory syndrome virus have large configuration and toxicity difference, so that the types of the virus are various, and a single vaccine has poor cross immunity on various types of strains and cannot achieve an effective prevention effect, so that the effect of inoculating the PRRS vaccine in actual production is very small.
In view of this, the present application is specifically made.
Disclosure of Invention
The invention aims to provide a composition for preventing and treating porcine reproductive and respiratory syndrome, a preparation method and application thereof, so as to solve the problems.
In order to achieve the above purpose, the invention adopts the following technical scheme:
a composition for preventing and treating porcine reproductive and respiratory syndrome comprises the following raw materials in parts by weight:
40-50 parts of alpha-glycerol monolaurate, 30-40 parts of Chinese herbal medicines, 10-20 parts of acidifier and 5-10 parts of plant essential oil;
the Chinese herbal medicine comprises, by weight, 20-30 parts of mulberry leaves, 20-30 parts of moringa seeds, 15-25 parts of bezoar and 10-20 parts of blackberrylily rhizome.
When the virus invades a latent animal body, the alpha-monolaurin can be quickly absorbed by small intestine, enters blood through portal vein, quickly enters lymph fluid for storage, is absorbed into the bacteria or virus through an outer membrane, and destroys the lipid bilayer of the bacterial or virus envelope, thereby inhibiting the complete structure of the bacteria or virus and achieving the effect of inhibiting and killing the bacteria or virus. In addition, the feed additive also has the functions of improving the growth performance of piglets and regulating intestinal flora; the composition of flora of gastrointestinal contents of weaned piglets can be regulated and controlled, and diarrhea caused by weaning of the piglets is reduced; can affect the signal transduction function of T cells by regulating lipid dynamic force to achieve the effect of regulating the immune function and regulating the proliferation of immune cells, and has obvious inhibition effect on proinflammatory immune factors such as IL-2, IL-10, IFN-gamma, TNF-alpha and the like.
Multiple Chinese herbal medicines are combined together to jointly exert the effects: the mulberry leaves contain abundant compounds such as flavonoid, alkaloid, polysaccharide and the like, and have the effects of dispelling wind and heat, clearing lung and moistening dryness, calming liver and improving eyesight, cooling blood and stopping bleeding and the like; the moringa seeds are rich in grease, protein, polysaccharide, polyphenol, various amino acids and the like, and have the effects of enhancing physical strength, treating anemia, inhibiting germs, expelling parasites and the like; the calculus bovis has tranquilizing, analgesic, antipyretic, and anticonvulsive effects; strengthening heart and improving cardiac function; can promote bile secretion and protect experimental liver injury; has expectorant, antitussive, and respiratory exciting effects; increasing red blood cells in peripheral blood; also has anti-inflammatory, anti-pathogenic microorganism, antioxidant and tumor growth inhibiting effects; rhizoma Belamcandae has effects of clearing away heat and toxic materials, resolving hard mass, relieving inflammation, relieving swelling and pain, relieving cough, and eliminating phlegm.
The acidifier has the effect of lowering pH value of feed in digestive tract, and can provide animal with novel additive with optimum digestive tract environment. The acidifying agent can purify drinking water, inhibit and remove biofilm, and reduce intestinal diseases caused by drinking water pollution; buffering and slow release, intestinal regulation and release, continuous inhibition of harmful bacteria in intestinal tracts and promotion of the propagation of beneficial bacteria; promote the secretion and activity of digestive enzyme, promote the absorption and utilization of nutrient substances; relieving diarrhea and reduced food consumption caused by heat stress, and stress such as material change and group transfer.
The plant essential oil has broad-spectrum antibacterial activity, and can inhibit and kill some bacteria, fungi and viruses. Has antioxidant effect, and can reduce damage of free radicals to organism and relieve oxidative stress; can improve the secretion and activity of endogenous enzyme, improve intestinal microbial flora, obviously improve the production performance of animals and improve the feed reward; can improve the immunity of animals by its antibacterial action, increasing the weight of immune organs and enhancing the activity of immune cells. The feed can reduce the mildew of the feed and the generation of mycotoxin and prolong the storage life of the feed through the bacteriostatic effect on common mould in the feed.
Alternatively, in the raw material of the composition for preventing and treating porcine reproductive and respiratory syndrome, the α -glycerol monolaurate may be any value between 40 parts, 41 parts, 42 parts, 43 parts, 44 parts, 45 parts, 46 parts, 47 parts, 48 parts, 49 parts, 50 parts, and 40-50 parts; the Chinese herbal medicine can be any value of 30 parts, 31 parts, 32 parts, 33 parts, 34 parts, 35 parts, 36 parts, 37 parts, 38 parts, 39 parts, 40 parts and 30-40 parts; the acidulant can be any value between 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, and 10-20 parts; the plant essential oil can be any value between 5 parts, 6 parts, 7 parts, 8 parts, 9 parts, 10 parts and 5-10 parts. The mulberry leaves can be 20 parts, 21 parts, 22 parts, 23 parts, 24 parts, 25 parts, 26 parts, 27 parts, 28 parts, 29 parts, 30 parts and any value between 20 and 30 parts in the weight of the Chinese herbal medicine unit; the moringa seeds can be any value between 20 parts, 21 parts, 22 parts, 23 parts, 24 parts, 25 parts, 26 parts, 27 parts, 28 parts, 29 parts, 30 parts and 20-30 parts; the bezoar bovis may be any one of 15 parts, 16 parts, 17 parts, 18 parts, 19 parts, 20 parts, 21 parts, 22 parts, 23 parts, 24 parts, 25 parts, and 15-25 parts; the blackberry lily can be any value between 10 parts, 11 parts, 12 parts, 13 parts, 14 parts, 15 parts, 16 parts, 17 parts, 18 parts, 19 parts, 20 parts and 10-20 parts.
Preferably, the acidifier comprises the following components in part by weight in unit weight:
40-50 parts of fumaric acid, 40-50 parts of citric acid, 15-25 parts of formic acid and 15-25 parts of sorbic acid.
Fumaric acid has antibacterial effect on Staphylococcus, Streptococcus and Escherichia coli; formic acid has inhibitory effect on salmonella, fungi, clostridium and gram-positive coccus, and can prevent feed mould proliferation and increase feeding ability; sorbic acid has inhibitory effect on growth of yeast and mold. Citric acid and fumaric acid can also be complexed with calcium, iron, zinc and other elements to accelerate absorption of organisms.
Alternatively, fumaric acid may be any value between 40 parts, 41 parts, 42 parts, 43 parts, 44 parts, 45 parts, 46 parts, 47 parts, 48 parts, 49 parts, 50 parts, and 40-50 parts per unit weight of the acidulant; the citric acid may be any value between 40 parts, 41 parts, 42 parts, 43 parts, 44 parts, 45 parts, 46 parts, 47 parts, 48 parts, 49 parts, 50 parts and 40-50 parts; formic acid can be any value between 15 parts, 16 parts, 17 parts, 18 parts, 19 parts, 20 parts, 21 parts, 22 parts, 23 parts, 24 parts, 25 parts, and 15-25 parts; sorbic acid can be any value between 15 parts, 16 parts, 17 parts, 18 parts, 19 parts, 20 parts, 21 parts, 22 parts, 23 parts, 24 parts, 25 parts, and 15-25 parts.
Preferably, the vegetable essential oil comprises the following components in parts by weight:
40-60 parts of geranium, 20-30 parts of cinnamon, 20-30 parts of thymol and 10-20 parts of pepper essential oil.
Thymol inhibits the growth of salmonella, the essential oil of pepper has a good inhibition effect on escherichia coli, geranium has an excellent inhibition effect, cinnamon has a function of enhancing non-specific immunity, and the effect is more remarkable when several plant essential oils are used in combination.
Alternatively, the geranium may be any value between 40 parts, 41 parts, 42 parts, 43 parts, 44 parts, 45 parts, 46 parts, 47 parts, 48 parts, 49 parts, 50 parts, 51 parts, 52 parts, 53 parts, 54 parts, 55 parts, 56 parts, 57 parts, 58 parts, 59 parts, 60 parts and 40-60 parts per unit weight of the plant essential oil; cinnamon may be and range anywhere from 20 to 30 parts; thymol may be any of 20 parts, 21 parts, 22 parts, 23 parts, 24 parts, 25 parts, 26 parts, 27 parts, 28 parts, 29 parts, 30 parts and 20 to 30 parts; the pepper essential oil can be any value between 10 parts, 11 parts, 12 parts, 13 parts, 14 parts, 15 parts, 16 parts, 17 parts, 18 parts, 19 parts, 20 parts and 10-20 parts.
Preferably, the alpha-glycerol monolaurate has a purity of 95% or more.
The alpha-Glycerol Monolaurate (GML) has higher purity and obvious effect.
A preparation method of the composition for preventing and treating porcine reproductive and respiratory syndrome comprises the following steps:
mixing raw materials including the alpha-monolaurin, the herbal medicine, the acidulant, and the plant essential oil to obtain the composition.
Preferably, the preparation method of the alpha-glycerol monolaurate comprises the following steps:
heating glycerol and lauric acid to react to obtain crude monolaurin, and distilling to obtain refined alpha-monolaurin.
Preferably, the reaction uses p-toluenesulfonic acid as a catalyst;
preferably, the temperature of the reaction is 180-200 ℃, and the time is 2-3 h;
preferably, the distillation comprises a first-stage molecular distillation, a second-stage molecular distillation, a third-stage molecular distillation and a fourth-stage molecular distillation which are sequentially carried out;
preferably, the flow rate of the material liquid of the primary molecular distillation is 180-220mL/h, the distillation temperature is 110-130 ℃, the condensation temperature is 75-85 ℃, and the operation pressure is 0.05-0.15 Pa;
preferably, the distillation temperatures of the secondary molecular distillation, the tertiary molecular distillation and the quaternary molecular distillation are each independently 95 to 105 ℃, the condensation temperatures are each independently 45 to 55 ℃, and the operating pressures are each independently 0.5 to 1.5 Pa.
Preferably, the Chinese herbal medicine is pulverized before use;
preferably, the particle size of the Chinese herbal medicine after being crushed is 5-30 μm.
Alternatively, the particle size of the herb after pulverization may be any one of 5 μm, 10 μm, 15 μm, 20 μm, 25 μm, 30 μm, and 5 to 30 μm.
The application of the composition for preventing and treating the porcine reproductive and respiratory syndrome is used for preparing a medicament for preventing and treating the porcine reproductive and respiratory syndrome.
Compared with the prior art, the invention has the beneficial effects that:
according to the composition for preventing and treating the porcine reproductive and respiratory syndrome, the alpha-monolaurate, the Chinese herbal medicines, the acidifier and the plant essential oil are combined, so that the growth performance of piglets can be improved, the immunity of the piglets is improved, viruses are resisted, the propagation of the viruses is inhibited, and the porcine reproductive and respiratory syndrome is effectively prevented and treated; the composition for preventing and treating the porcine reproductive and respiratory syndrome does not contain hormones and antibiotics, accords with the future antibiotic resistance reduction and environmental protection trend of the industry, and has great practical significance for promoting the prevention and control of the porcine reproductive and respiratory syndrome;
the preparation method of the composition for preventing and treating porcine reproductive and respiratory syndrome provided by the application is simple in process and low in cost.
Drawings
To more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings that are required to be used in the embodiments will be briefly described below, and it should be understood that the following drawings only illustrate some embodiments of the present invention, and therefore should not be considered as limiting the scope of the present invention.
Fig. 1 is a schematic diagram illustrating the effect of the composition for preventing and treating porcine reproductive and respiratory syndrome provided by the present application on piglet fecal coliform;
FIG. 2 is a schematic illustration of the effect of the compositions for preventing and treating porcine reproductive and respiratory syndrome provided herein on Salmonella coproagula of piglets;
FIG. 3 is a diagram showing the S/P value of porcine reproductive and respiratory syndrome virus antibody in piglet serum.
Detailed Description
The terms as used herein:
"prepared from … …" is synonymous with "comprising". The terms "comprises," "comprising," "includes," "including," "has," "having," "contains," "containing," or any other variation thereof, as used herein, are intended to cover a non-exclusive inclusion. For example, a composition, process, method, article, or apparatus that comprises a list of elements is not necessarily limited to only those elements but may include other elements not expressly listed or inherent to such composition, process, method, article, or apparatus.
The conjunction "consisting of … …" excludes any unspecified elements, steps or components. If used in a claim, the phrase is intended to claim as closed, meaning that it does not contain materials other than those described, except for the conventional impurities associated therewith. When the phrase "consisting of … …" appears in a clause of the subject matter of the claims rather than immediately after the subject matter, it defines only the elements described in the clause; other elements are not excluded from the claims as a whole.
When an amount, concentration, or other value or parameter is expressed as a range, preferred range, or as a range of upper preferable values and lower preferable values, this is to be understood as specifically disclosing all ranges formed from any pair of any upper range limit or preferred value and any lower range limit or preferred value, regardless of whether ranges are separately disclosed. For example, when the range "1 ~ 5" is disclosed, the ranges described should be construed to include the ranges "1 ~ 4", "1 ~ 3", "1 ~ 2 and 4 ~ 5", "1 ~ 3 and 5", and the like. When a range of values is described herein, unless otherwise stated, the range is intended to include the endpoints thereof and all integers and fractions within the range.
In these examples, the parts and percentages are by mass unless otherwise indicated.
"part by mass" means a basic unit of measure indicating a mass ratio of a plurality of components, and 1 part may represent any unit mass, for example, 1g or 2.689 g. If we say that the part by mass of the component A is a part by mass and the part by mass of the component B is B part by mass, the ratio of the part by mass of the component A to the part by mass of the component B is a: b. alternatively, the mass of the A component is aK and the mass of the B component is bK (K is an arbitrary number, and represents a multiple factor). It is unmistakable that, unlike the parts by mass, the sum of the parts by mass of all the components is not limited to 100 parts.
"and/or" is used to indicate that one or both of the illustrated conditions may occur, e.g., a and/or B includes (a and B) and (a or B).
Embodiments of the present invention will be described in detail below with reference to specific examples, but those skilled in the art will appreciate that the following examples are only illustrative of the present invention and should not be construed as limiting the scope of the present invention. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products available commercially.
Example 1
The embodiment provides a composition for preventing and treating porcine reproductive and respiratory syndrome, which comprises the following raw materials in parts by weight: 50 parts of alpha-monolaurin, 40 parts of Chinese herbal medicines, 20 parts of acidifier and 10 parts of plant essential oil.
The alpha-monolaurate is high-purity alpha-monolaurate (purity is more than or equal to 95%). The compound Chinese herbal medicine comprises mulberry leaf, moringa seed, bezoar and blackberry lily, and the components in unit weight proportion are as follows: 30 parts of mulberry leaf, 30 parts of moringa seed, 25 parts of bezoar and 20 parts of blackberry lily (after the components are uniformly mixed according to the formula, 35 parts of Chinese herbal medicines by weight are obtained by independent measurement and added into the composition). The components of the acidifier in unit weight proportion comprise 50 parts of fumaric acid, 50 parts of citric acid, 25 parts of formic acid and 25 parts of sorbic acid. The plant essential oil comprises, by unit weight, 60 parts of geranium, 30 parts of cinnamon, 30 parts of thymol and 20 parts of pepper essential oil.
A method of preparing a composition, the method comprising the steps of:
1: preparing raw materials according to the mass fraction, and inspecting to be qualified;
2: the alpha-monolaurate is more than 95% pure, and the process method comprises the following steps: the molar ratio of glycerol to lauric acid was 2: 1, preparing glycerol monolaurate by using p-toluenesulfonic acid for catalytic synthesis, wherein the reaction temperature is 190 ℃, and the reaction time is 2.5 hours, so as to obtain crude glycerol monolaurate. Then, molecular distillation is carried out to purify the crude monolaurin, and the optimal process parameters for extracting the monolaurin by primary molecular distillation are as follows: the feed liquid flow rate is 200ml/h, the distillation temperature is 120 ℃, the condensation temperature is 80 ℃ and the operation pressure is 0.1 Pa. Then, the distillation temperature is adjusted to 100 ℃, the condensation temperature is adjusted to 50 ℃, and secondary distillation, tertiary distillation and quaternary distillation are carried out when the operation pressure is 1Pa, so that the monolaurin with the purity of not less than 95 percent is obtained.
3: pulverizing the Chinese herbal mixture with common pulverizer, and pulverizing with superfine pulverizer for more than 3 hr to obtain powder with particle size of 5-30 μm.
4: the alpha-monolaurin, the Chinese herbal medicines, the acidifier and the essential oil are put into a trough mixer to be mixed for 60 minutes, and the rotating speed of the mixer is 300r/min, so that the composition for preventing and treating the porcine reproductive and respiratory syndrome is obtained.
Example 2
The embodiment provides a composition for preventing and treating porcine reproductive and respiratory syndrome, which comprises the following raw materials in parts by weight: 40 parts of alpha-monolaurin, 30 parts of Chinese herbal medicines, 10 parts of acidifier and 5 parts of plant essential oil.
The alpha-monolaurate is high purity alpha-monolaurate. The Chinese herbal medicine comprises mulberry leaf, moringa seed, bezoar and blackberry lily, and the components in unit weight proportion are as follows: 20 parts of mulberry leaf, 20 parts of moringa seed, 15 parts of bezoar and 10 parts of blackberry lily. The components of the acidifier in unit weight proportion comprise 40 parts of fumaric acid, 40 parts of citric acid, 15 parts of formic acid and 15 parts of sorbic acid. The plant essential oil comprises 40 parts of geranium, 20 parts of cinnamon, 20 parts of thymol and 10 parts of pepper essential oil according to the proportion in unit weight.
A method of preparing a composition, the method comprising the steps of:
1: preparing raw materials according to the mass fraction, and inspecting to be qualified;
2: the alpha-monolaurate is more than 95% pure, and the process method comprises the following steps: the molar ratio of glycerol to lauric acid was 2: 1, preparing glycerol monolaurate by using p-toluenesulfonic acid for catalytic synthesis, wherein the reaction temperature is 190 ℃, and the reaction time is 2.5 hours, so as to obtain crude glycerol monolaurate. Then, molecular distillation is carried out to purify the crude monolaurin, and the optimal process parameters for extracting the monolaurin by primary molecular distillation are as follows: the feed liquid flow rate is 200ml/h, the distillation temperature is 120 ℃, the condensation temperature is 80 ℃ and the operation pressure is 0.1 Pa. Then adjusting the distillation temperature to 100 ℃, adjusting the condensation temperature to 50 ℃, and carrying out secondary distillation, tertiary distillation and quaternary distillation when the operation pressure is 1Pa to obtain the monolaurin with the purity of not less than 95%.
3: pulverizing the Chinese herbal mixture with common pulverizer, and pulverizing with superfine pulverizer for more than 3 hr to obtain powder with particle size of 5-30 μm.
4: the alpha-monolaurin, the Chinese herbal medicines, the acidifier and the essential oil are put into a trough mixer to be mixed for 60 minutes, and the rotating speed of the mixer is 300r/min, so that the composition for preventing and treating the porcine reproductive and respiratory syndrome is obtained.
Example 3
The embodiment provides a composition for preventing and treating porcine reproductive and respiratory syndrome, which comprises the following raw materials in parts by weight: 45 parts of alpha-monolaurin, 35 parts of Chinese herbal medicines, 15 parts of acidifier and 8 parts of plant essential oil.
The alpha-monolaurate is high purity alpha-monolaurate. The Chinese herbal medicine comprises mulberry leaf, moringa seed, bezoar and blackberry lily, and the components in unit weight proportion are as follows: 25 parts of mulberry leaf, 25 parts of moringa seed, 20 parts of bezoar and 15 parts of blackberry lily. The components of the acidifier in unit weight proportion comprise 45 parts of fumaric acid, 45 parts of citric acid, 20 parts of formic acid and 20 parts of sorbic acid. The plant essential oil comprises 50 parts of geranium, 25 parts of cinnamon, 25 parts of thymol and 15 parts of pepper essential oil in unit weight ratio.
A method of preparing a composition, the method comprising the steps of:
1: preparing raw materials according to the mass fraction, and inspecting to be qualified;
2: the alpha-monolaurate is more than 95% pure, and the process method comprises the following steps: the molar ratio of glycerol to lauric acid was 2: 1, preparing glycerol monolaurate by using p-toluenesulfonic acid for catalytic synthesis, wherein the reaction temperature is 190 ℃, and the reaction time is 2.5 hours, so as to obtain crude glycerol monolaurate. Then, molecular distillation is carried out to purify the crude monolaurin, and the optimal process parameters for extracting the monolaurin by primary molecular distillation are as follows: the feed liquid flow rate is 200ml/h, the distillation temperature is 120 ℃, the condensation temperature is 80 ℃ and the operation pressure is 0.1 Pa. Then adjusting the distillation temperature to 100 ℃, adjusting the condensation temperature to 50 ℃, and carrying out secondary distillation, tertiary distillation and quaternary distillation when the operation pressure is 1Pa to obtain the monolaurin with the purity of not less than 95%.
3: pulverizing the Chinese herbal mixture with common pulverizer, and pulverizing with superfine pulverizer for more than 3 hr to obtain powder with particle size of 5-30 μm.
4: the alpha-monolaurin, the Chinese herbal medicines, the acidifier and the essential oil are put into a trough mixer to be mixed for 60 minutes, and the rotating speed of the mixer is 300r/min, so that the composition for preventing and treating the porcine reproductive and respiratory syndrome is obtained.
The composition for preventing and treating porcine reproductive and respiratory syndrome provided by the application can be used as an additive and compounded with a basic feed to obtain a compound feed. In compounding, 1-5kg of the composition is generally added per 1 ton of basal pig ration.
Comparative example 1
Basal diet was used as control.
Comparative example 2
Unlike example 1, no mulberry leaves were used in the herbal medicine.
Comparative example 3
In contrast to example 2, the purity of the α -glycerol monolaurate was only 90%.
180 24 day old piglets were selected for the trial and divided into 6 treatment groups of 3 replicates each with 10 replicates each. The control group 1 was fed a basal diet, and the control group 2 (composition obtained in comparative example 2), the control group 3 (composition obtained in comparative example 3), the test group 1 (composition obtained in example 1), the test group 2 (composition obtained in example 2), and the test group 3 (composition obtained in example 3) were supplemented with 0.3 wt% of the composition to the basal diet for 21 days.
Through experiments, the data of the influence of the composition on the piglet growth indexes are obtained, and are specifically shown in the following table 1:
TABLE 1 Effect of compositions on piglet growth index
Item | Daily gain/Kg | Meat ratio of |
Control group | ||
1 | 0.26±0.02a | 1.57±0.02b |
|
0.27±0.01a | 1.55±0.01b |
|
0.27±0.02a | 1.54±0.01b |
|
0.33±0.02b | 1.46±0.01a |
|
0.31±0.02b | 1.48±0.01a |
|
0.31±0.02b | 1.48±0.02a |
Note: the same letter in the same row indicates no significant difference, and different letters indicate significant difference (P < 0.05). The same applies to Table 2 below.
As can be seen from Table 1, there was no significant difference between the control groups 1-3 (P > 0.05); compared with the control groups 1-3, the weight gain of the test groups 1-3 is obviously improved (P is less than 0.05), the feed-meat ratio is obviously reduced (P is less than 0.05), and the test group 1 has the most outstanding advantages. The composition provided by the invention can obviously improve the growth performance of piglets.
The effect of the composition on fecal coliform bacteria and salmonella of piglets is shown in fig. 1 and fig. 2, respectively. As can be seen from FIGS. 1 and 2, there was no significant difference between the control groups 1 to 3 (P > 0.05); compared with the control groups 1-3, the numbers of escherichia coli and salmonella in the pig manure samples of the test groups 1-3 are obviously reduced (P is less than 0.05), wherein the numbers of the escherichia coli and the salmonella in the test group 1 are the lowest. The composition has a regulating effect on intestinal microorganisms of piglets, and can reduce the number of intestinal escherichia coli and salmonella.
Through experiments, data of the influence of the composition on the S/P value of the porcine reproductive and respiratory syndrome virus antibody in the piglet serum are obtained, and are specifically shown in the following table 1 and fig. 3:
TABLE 2 Effect of compositions on porcine reproductive and respiratory syndrome Virus antibody S/P values in piglet serum
| Control group | 1 | |
|
|
|
|
Mean value of | 0.327 | 0.323 | 0.328 | 0.261 | 0.263 | 0.266 | |
Maximum value | 0.352 | 0.335 | 0.346 | 0.284 | 0.288 | 0.289 | |
|
0% | 0% | 0% | 0% | 0% | 0% |
Note: the level of the blue-ear disease antibody is expressed by an S/P value, the S/P value is more than or equal to 0.4, the serum antibody of the test piglet is positive in blue-ear disease, and the S/P value is less than 0.4, the serum antibody of the test piglet is negative.
As can be seen from Table 2 and FIG. 3, there was no significant difference between the control groups 1 to 3 (P > 0.05); compared with control groups 1-3, the average value of the S/P value of the porcine reproductive and respiratory syndrome virus antibody in the serum of piglets of the test groups 1-3 is remarkably reduced (P is less than 0.05), the positive rates of the antibody are all 0 percent (P is more than 0.05), and the effect of the test group 1 is obvious. The composition can reduce the level of porcine reproductive and respiratory syndrome virus antibody in the serum of weaned pigs.
In conclusion, the composition provided by the invention can reduce the antibody level of the porcine reproductive and respiratory syndrome virus, so that the antibody level of a swinery is maintained at a lower level, the potential outbreak risk of the porcine reproductive and respiratory syndrome virus is reduced, the composition conforms to the trend of reducing the alternative resistance and protecting the environment in the future of the industry, and has a great practical significance for promoting the control of the porcine reproductive and respiratory syndrome virus.
Finally, it should be noted that: the above embodiments are only used to illustrate the technical solution of the present invention, and not to limit the same; while the invention has been described in detail and with reference to the foregoing embodiments, it will be understood by those skilled in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some or all of the technical features may be equivalently replaced; and the modifications or the substitutions do not make the essence of the corresponding technical solutions depart from the scope of the technical solutions of the embodiments of the present invention.
Furthermore, those skilled in the art will appreciate that while some embodiments herein include some features included in other embodiments, rather than other features, combinations of features of different embodiments are meant to be within the scope of the invention and form different embodiments. For example, in the claims above, any of the claimed embodiments may be used in any combination. The information disclosed in this background section is only for enhancement of understanding of the general background of the invention and should not be taken as an acknowledgement or any form of suggestion that this information forms the prior art already known to a person skilled in the art.
Claims (10)
1. The composition for preventing and treating porcine reproductive and respiratory syndrome is characterized by comprising the following raw materials in parts by weight:
40-50 parts of alpha-glycerol monolaurate, 30-40 parts of Chinese herbal medicines, 10-20 parts of acidifier and 5-10 parts of plant essential oil;
the Chinese herbal medicine comprises, by weight, 20-30 parts of mulberry leaves, 20-30 parts of moringa seeds, 15-25 parts of bezoar and 10-20 parts of blackberrylily rhizome.
2. The composition according to claim 1, wherein the acidulant comprises, in parts by weight per unit weight:
40-50 parts of fumaric acid, 40-50 parts of citric acid, 15-25 parts of formic acid and 15-25 parts of sorbic acid.
3. The composition as claimed in claim 1, wherein the vegetable essential oil comprises, in parts by weight per unit weight:
40-60 parts of geranium, 20-30 parts of cinnamon, 20-30 parts of thymol and 10-20 parts of pepper essential oil.
4. A composition according to any of claims 1 to 3, wherein the alpha-glycerol monolaurate is greater than or equal to 95% pure.
5. A method for preparing a composition for preventing and treating porcine reproductive and respiratory syndrome according to any one of claims 1 to 4, comprising:
mixing raw materials including the alpha-monolaurin, the herbal medicine, the acidulant, and the plant essential oil to obtain the composition.
6. The method according to claim 5, wherein the method for preparing the glycerol α -monolaurate comprises:
heating glycerol and lauric acid to react to obtain crude monolaurin, and distilling to obtain refined alpha-monolaurin.
7. The production method according to claim 6, wherein the reaction uses p-toluenesulfonic acid as a catalyst.
8. The method as claimed in claim 6, wherein the reaction temperature is 180-200 ℃ and the reaction time is 2-3 h;
preferably, the distillation comprises a first-stage molecular distillation, a second-stage molecular distillation, a third-stage molecular distillation and a fourth-stage molecular distillation which are sequentially carried out;
preferably, the flow rate of the material liquid of the primary molecular distillation is 180-220mL/h, the distillation temperature is 110-130 ℃, the condensation temperature is 75-85 ℃, and the operation pressure is 0.05-0.15 Pa;
preferably, the distillation temperatures of the secondary molecular distillation, the tertiary molecular distillation and the quaternary molecular distillation are each independently 95 to 105 ℃, the condensation temperatures are each independently 45 to 55 ℃, and the operating pressures are each independently 0.5 to 1.5 Pa.
9. The method of any one of claims 5-8, wherein the herbs are comminuted prior to use;
preferably, the particle size of the Chinese herbal medicine after being crushed is 5-30 μm.
10. Use of a composition according to any one of claims 1 to 4 for the prevention and treatment of porcine reproductive and respiratory syndrome for the preparation of a medicament for the prevention and treatment of porcine reproductive and respiratory syndrome.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010788546.3A CN111700957A (en) | 2020-08-07 | 2020-08-07 | Composition for preventing and treating porcine reproductive and respiratory syndrome and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010788546.3A CN111700957A (en) | 2020-08-07 | 2020-08-07 | Composition for preventing and treating porcine reproductive and respiratory syndrome and preparation method and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111700957A true CN111700957A (en) | 2020-09-25 |
Family
ID=72547214
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010788546.3A Pending CN111700957A (en) | 2020-08-07 | 2020-08-07 | Composition for preventing and treating porcine reproductive and respiratory syndrome and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111700957A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114344356A (en) * | 2021-12-31 | 2022-04-15 | 福建傲农生物科技集团股份有限公司 | Bacteriostatic composite active substance microcapsule particles and preparation method and application thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105418417A (en) * | 2015-12-22 | 2016-03-23 | 杭州富春食品添加剂有限公司 | Preparation method for high-purity glyceryl monolaurate |
CN106620689A (en) * | 2016-11-29 | 2017-05-10 | 浙江美保龙生物技术有限公司 | Dilution for live vaccine of porcine reproductive and respiratory syndrome |
-
2020
- 2020-08-07 CN CN202010788546.3A patent/CN111700957A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105418417A (en) * | 2015-12-22 | 2016-03-23 | 杭州富春食品添加剂有限公司 | Preparation method for high-purity glyceryl monolaurate |
CN106620689A (en) * | 2016-11-29 | 2017-05-10 | 浙江美保龙生物技术有限公司 | Dilution for live vaccine of porcine reproductive and respiratory syndrome |
Non-Patent Citations (5)
Title |
---|
李晓琳,等: "辣木的抗菌消炎作用及其在畜牧生产中的应用", 《动物营养学报》 * |
王小燕,等: "桑叶饲料对母猪生产性能、血液生理生化和免疫指标的影响", 《饲料工业》 * |
管培庆,等: "月桂酸单甘酯的合成与提纯", 《广州化工》 * |
郭锡钦: "α-单月桂酸甘油酯对仔猪免疫功能及猪繁猪繁殖与呼吸综合征病毒的影响研究", 《浙江农业大学硕士学位论文》 * |
雷春龙,等: "饲粮中添加桑枝叶干粉对肥育猪生产性能、血清免疫指标与抗氧化能力的影响", 《畜牧与兽医》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114344356A (en) * | 2021-12-31 | 2022-04-15 | 福建傲农生物科技集团股份有限公司 | Bacteriostatic composite active substance microcapsule particles and preparation method and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101214311B (en) | Compound scutellaria injection for treating fowls and domestic animals infectious disease and preparation thereof | |
CN111758852A (en) | Additive premix for improving intestinal health of broiler chickens and application thereof | |
WO2009151048A1 (en) | Composition for feed, and feed comprising the same | |
CN105287790B (en) | A kind of fevervine extract and its application | |
CN110354139B (en) | Composition for resisting porcine epidemic diarrhea virus infection and application thereof | |
CN112336828A (en) | Fermented traditional Chinese medicine microecological preparation for preventing and treating piglet diarrhea and preparation method thereof | |
CN112136965B (en) | Immunity-enhancing and growth-promoting fermented Chinese herbal medicine feed additive and preparation method thereof | |
CN110692863A (en) | Plant extract feed additive for improving liver and intestine protecting capability of tilapia | |
CN114568602B (en) | Traditional Chinese medicine compound for improving growth performance and organism immunity of broiler chickens and preparation method and application thereof | |
CN111700957A (en) | Composition for preventing and treating porcine reproductive and respiratory syndrome and preparation method and application thereof | |
KR950011733B1 (en) | Disease resistance ration and feed additive for cattles and swines | |
CN104399017A (en) | Composition for prevention and treatment of female vulva inflammation | |
CN106578491A (en) | Mixed feed additive for replacing antibiotics and preparation method of mixed feed additive | |
CN113750172B (en) | Weight-losing composition and application thereof in preparation of weight-losing product | |
CN113967243B (en) | Fermented traditional Chinese medicine preparation for preventing and treating diarrhea of poultry and preparation method thereof | |
CN114177232A (en) | Extraction method of tea polyphenol extract, extracted tea polyphenol extract and application thereof | |
KR102223084B1 (en) | Antimicrobial immune-enhancing livestock feed additives using myrrh and gold and antimicrobial immune-enhancing livestock feed additives prepared using the same | |
KR102322119B1 (en) | Feedstuff composition containing Moringa oleifera and Formulated feedstuff for pig containing the same | |
Demeyer | Influence of calcium peroxide on fermentation pattern and protozoa in the rumen | |
CN101001637A (en) | The use of paeonia and extracts thereof with growth promoting activity in veterinary medicine and zootechnics | |
CN111587953B (en) | Traditional Chinese medicine compound feed additive for replacing antibiotics and preparation method and application thereof | |
CN118045047B (en) | Bufonis venenum granule prepared by superfine pulverizing technology | |
KR101921060B1 (en) | Antimicrobial or antifungal composition comprising Houttuynia cordata THUNB.'s extracts and silicon | |
Feng | Research on antibiotic-induced intestinal flora imbalance in livestock and its treatment | |
CN116784432A (en) | Plant essential oil product for relieving diarrhea of weaned pigs and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200925 |